Literature DB >> 14755484

Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies.

Jun Li1, Karen Krajewski, Richard A Lewis, Michael E Shy.   

Abstract

Hereditary neuropathy with liability to pressure palsies (HNPP) provides a human model to investigate the role of PMP22 in myelinated peripheral nerve, since the disease is caused by a deletion of one of the two PMP22 alleles. To systematically characterize the phenotype of HNPP, we prospectively evaluated the clinical features and electrophysiological findings in 17 genetically confirmed patients, 7 men and 10 women, ranging in age from 9 to 66 years (mean, 41 +/- 13). Fifteen symptomatic patients presented with episodes of transient focal weakness or sensory loss that were usually related to particular activities causing nerve compression, including stretching or minor repetitive focal trauma. No patient sought medical attention for symptoms of a symmetric polyneuropathy. Neurological examinations were either normal or mildly abnormal. Neither focal slowing of nerve conduction studies, nor reduction in compound muscle action potential (CMAP) or sensory nerve action potential (SNAP) amplitudes consistently predicted the site of symptoms. We conclude that the majority of patients with HNPP present with transient, recurrent, focal symptoms of weakness or sensory loss in the distribution of individual nerves or plexus, and that a diffuse symmetric sensorimotor polyneuropathy is an unusual presentation of HNPP. These studies suggest that the function of PMP22, at least in part, is to stabilize myelin so that it will be protected from injuries resulting from repetitive, minor trauma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755484     DOI: 10.1002/mus.10521

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

1.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 2.  Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies.

Authors:  Kinga Szigeti; Eva Nelis; James R Lupski
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

3.  Charcot-Marie-Tooth disease subtypes and genetic testing strategies.

Authors:  Anita S D Saporta; Stephanie L Sottile; Lindsey J Miller; Shawna M E Feely; Carly E Siskind; Michael E Shy
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

Review 4.  Inherited neuropathies.

Authors:  Jun Li
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

5.  Neuropathy in a human without the PMP22 gene.

Authors:  Mario Andre Saporta; Istvan Katona; Xuebao Zhang; Helen P Roper; Louise McClelland; Fiona Macdonald; Louise Brueton; Julian Blake; Ueli Suter; Mary M Reilly; Michael E Shy; Jun Li
Journal:  Arch Neurol       Date:  2011-06

6.  Abnormal junctions and permeability of myelin in PMP22-deficient nerves.

Authors:  Jiasong Guo; Leiming Wang; Yang Zhang; Jiawen Wu; Sezgi Arpag; Bo Hu; Beat A Imhof; Xinxia Tian; Bruce D Carter; Ueli Suter; Jun Li
Journal:  Ann Neurol       Date:  2014-02-20       Impact factor: 10.422

Review 7.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

8.  PMP22 expression in dermal nerve myelin from patients with CMT1A.

Authors:  Istvan Katona; Xingyao Wu; Shawna M E Feely; Stephanie Sottile; Carly E Siskind; Lindsey J Miller; Michael E Shy; Jun Li
Journal:  Brain       Date:  2009-05-15       Impact factor: 13.501

9.  Classification and diagnosis of the inherited neuropathies.

Authors:  Mary M Reilly
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

10.  Conduction block in PMP22 deficiency.

Authors:  Yunhong Bai; Xuebao Zhang; Istvan Katona; Mario Andre Saporta; Michael E Shy; Heather A O'Malley; Lori L Isom; Ueli Suter; Jun Li
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.